Monthly Archives: April 2011

Common genetic variant linked to pulmonary fibrosis risk NIH-funded genome study could lead to increased knowledge of lung-scarring diseases. Scientists funded by the National Institutes of Health have identified a common genetic variant associated with substantially increased risk of developing … Continue reading →

San Diego, CA – Apr 19, 2011 — Amira Pharmaceuticals, Inc.  announced today that AM152, the company’s lead LPA1 antagonist, has been  granted an orphan drug designation by the U.S. Food and Drug Administration for  the treatment of idiopathic pulmonary … Continue reading →

ImmuneWorks, Inc. recently partnered with The University of Vermont in Burlington to conduct a clinical trial for a new idiopathic pulmonary fibrosis (IPF) treatment. The Phase I clinical trial will evaluate the safety, tolerability, and biologic effects of three doses … Continue reading →

LAS VEGAS – The 2005 revision of the lung allocation system for U.S. lung transplants succeeded, resulting in fewer patients dying while on the lung waiting list, Dr. Robert M. Kotloff said at the annual meeting of the National Association … Continue reading →

CHARLESTON, SC (WCSC) – MUSC performed its first lung transplant in more than 15 years March 9. Before the program was approved, anyone needing a lung transplant had to travel out of state. Full Article: http://www.live5news.com/story/14317398/musc-launches-new-lung-transplantation-program www.ipftoday.com

A group of researchers at the Institute for Biomedical Research of Barcelona is working on a pioneering treatment for idiopathic pulmonary fibrosis based on an innovative hypothesis: the transplant of type II pneumocytes, the cells that allow the lung to … Continue reading →

New York, NY, March 23, 2011 Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled “MicroRNAs: A Potential … Continue reading →